ALFA Finder| EBITDA Margin: guided vs achieved | 5.00% achieved Guided 5.00%; confirmed by management |
|---|---|
| Management target | Revenue 23.0% FY27 |
| Revenue growth | 38.2% YoY growth, driven by 19.6% organic and 20.4% inorganic gains. |
|---|---|
| Margins | Structural expansion; EBITDA margin hit 5% due to scale and MedTech. |
| Demand visibility | Strong; IPM growing double digits led by volume across all therapy areas. |
| Management confidence | High; confident in organic scalability and achieving full-year targets early. |
Growth
Revenue grew 40% on a like-for-like basis; organic growth was 19.6% while inorganic contributions from past acquisitions added 20.4%.
Outlook
Management maintains FY27 revenue growth guidance of 23% excluding new acquisitions and a 50% EBITDA-to-operating cash flow conversion target.
Risks
High reliance on past M&A for growth; significant minority interest leakage (27% of profit) via non-wholly owned subsidiaries.
Last quarter's promises, checked
Delivered
- Guided 30% LFL Revenue Growth → delivered 31.5% (= BEAT)
- Guided 4% EBITDA Margin → delivered 4% (= BEAT)
- Guided 50% EBITDA-to-OCF conversion → delivered 104.6cr OCF on 86cr Q4 EBITDA (= BEAT)
Partly delivered
- Guided 25-27% Minority Interest leakage → delivered 27% in current Q1 (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: ENTERO. Summary written with AI assistance from the document.
Entero Healthcare Solutions Ltd: key numbers
- Share price
- ₹2,019.10
- Market cap
- ₹8,796 Cr
- Revenue (annual)
- ₹6,591 Cr
- Net profit (annual)
- ₹115.0 Cr
- P/E (TTM)
- 63.1×Sector 54.5×
- Promoter holding
- 52.40%+0.00% QoQ
- FII holding
- 5.76%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Entero Healthcare Solutions Ltd
All →Entero Healthcare Solutions Legal & Regulatory
Entero's subsidiary Vasavi Medicare faces an INR 11.87 crore customer default. Vasavi has fully provided for the dues and plans legal recovery action.
- Value
- ₹11.87 Cr
Entero Healthcare Solutions Investor Presentation: Key Takeaways
Q2FY27 revenue Rs 2,087 Cr (+32.9% reported, +34.7% LFL), EBITDA Rs 111 Cr at 5.3% margin, PAT Rs 61 Cr (+66%). Strategy: consolidate fragmented distribution and scale MedTech (IVD, cardio-ortho).
Entero Healthcare Solutions Q2 FY27 Results: Net Profit ₹60.7 Cr, Up 65.8% YoY
Entero Healthcare Solutions Ltd reported revenue from operations of ₹2,087 Cr (+32.9% YoY) and net profit of ₹60.7 Cr (+65.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹60.7 Cr · +65.8% YoY
Entero Healthcare Solutions Other Announcement
Entero Healthcare Solutions filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing reports promoter and public holdings, with no transaction or corporate event.
Entero Healthcare Solutions Board Meeting Date
Entero Healthcare Solutions scheduled a board meeting for November 04, 2026, to consider and approve unaudited financial results for the quarter ended September 30, 2026.
Entero Healthcare Solutions Other Announcement
Entero Healthcare Solutions Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ending September 2026.